Clinical Trials for Non-Small Cell Lung Cancer

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with locally advanced or metastatic solid tumor malignancies, evaluating the safety and tolerability of TransCon IL-2 β/γ, a long-acting IL-2Rβ/γ receptor-targeting prodrug, alone or in combination with pembrolizumab, TransCon TLR7/8 agonist, or other anticancer therapies.

ClinicalTrials.gov ID: NCT05081609

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the safety and feasibility of combining liver SBRT with the immune checkpoint inhibitor Pembrolizumab, which targets PD-1, in adult patients with metastatic non-small cell lung cancer and liver metastases who are eligible for this immunotherapy.

ClinicalTrials.gov ID: NCT05430009

Restoring Sensitivity to Immunotherapy Post Failure to the Pacific Regimen: a Pilot Study of Combined Durvalumab (MEDI 4736) and Grid Therapy for Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the safety and efficacy of combining durvalumab, an anti-PD-L1 monoclonal antibody, with grid therapy in patients with non-small cell lung cancer who have progressed after the PACIFIC regimen. Eligible patients must have lesions suitable for grid therapy and may include those with polymetastatic disease, brain metastases, or local recurrences.

ClinicalTrials.gov ID: NCT05443971

A Phase 2 Study of First-line Sotorasib for Patients with Advanced KRAS G12C-mutant Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced KRAS G12C-mutant NSCLC, focusing on assessing the safety and efficacy of the KRAS G12C inhibitor sotorasib as a first-line treatment. Participants must have a KPS of 70% or greater, measurable disease, no prior therapy in the advanced setting, and meet specific organ function and biopsy consent criteria.

ClinicalTrials.gov ID: NCT06582771

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients over 18 with advanced solid tumors expressing high levels of EphA2, testing the safety and efficacy of BT5528, a targeted Bicycle Toxin Conjugate linked to MMAE, as a monotherapy and in combination with the PD-1 inhibitor nivolumab, particularly in ovarian, urothelial, lung, breast, head and neck, and gastric cancers after progression on standard treatments.

ClinicalTrials.gov ID: NCT04180371

A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with advanced nonsquamous non-small cell lung cancer who have not received prior systemic treatment and evaluates vudalimab, a bispecific antibody targeting PD-1 and CTLA-4, in combination with chemotherapy versus pembrolizumab plus chemotherapy for efficacy and safety.

ClinicalTrials.gov ID: NCT06173505

A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial focuses on patients with advanced solid tumors carrying KRAS or EGFR mutations who have relapsed or are refractory to standard treatments, using the oral SHP2 inhibitor HBI-2376 to target pathways involved in cancer cell survival and proliferation.

ClinicalTrials.gov ID: NCT05163028

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates TSR-022, a TIM-3 checkpoint inhibitor, as monotherapy or in combination with therapies such as anti-PD-1 drugs in adult patients with advanced or metastatic solid tumors, including NSCLC and HCC, who have previously been treated with standard therapies. Eligible patients should have measurable disease and agree to biopsies for TIM-3 expression assessment.

ClinicalTrials.gov ID: NCT02817633

A Multi-Center Phase 2 Study of Hippocampal Avoidance in Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adults with breast cancer or NSCLC with leptomeningeal metastases, using craniospinal irradiation with hippocampal avoidance via proton or VMAT to reduce neurological side effects while effectively treating the cancer. Participants require a KPS of ≥ 60 and suitable blood counts, and treatment is given over two weeks.

ClinicalTrials.gov ID: NCT06518057

Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with stage IV PD-L1 positive NSCLC that progressed after at least two doses of anti-PD-1/PD-L1 therapy, excluding specific cancer subtypes, and explores the efficacy and safety of combining healthy donor fecal microbiota transplants (hdFMT) with pembrolizumab, a PD-1 inhibitor.

ClinicalTrials.gov ID: NCT05669846